Hemoglobin subunit gamma gene promoter (HBG1 or HBG2 promoter) (HBG1/2 promoter)

The HBG1 and HBG2 gene promoters are regulatory DNA sequences controlling the transcription of the A-gamma (HBG1) and G-gamma (HBG2) hemoglobin subunit genes, which are expressed primarily in the fetal liver, spleen, and bone marrow[1][4][5]. These promoters play a pivotal role in the developmental regulation of hemoglobin production. In fetal life, the γ-globin genes are highly active, enabling the formation of fetal hemoglobin (HbF), which has a higher affinity for oxygen than adult hemoglobin. After birth, these genes are normally silenced and β-globin is expressed instead. Certain mutations or gene-editing strategies targeting the HBG1/2 promoters can maintain or reactivate γ-globin expression, providing clinical benefit in hemoglobinopathies such as sickle cell disease and β-thalassemia by increasing HbF levels and ameliorating disease severity[1][2][3][4][5]. The promoters are notable sites for therapeutic intervention via genetic or epigenetic modulation, even though they are not proteins or enzymes themselves.

Other names

Gamma-globin gene promoterHBG1 promoterHBG2 promoterGgamma/A-gamma promoterGy/Agamma promoter

Gene editing (e.g., CRISPR-Cas9) to disrupt cis-regulatory repressor binding sites, resulting in increased γ-globin and fetal hemoglobin (HbF) expression[3] Inhibition of repressor complex binding (such as BCL11A binding) to the promoter, reactivating γ-globin expression[1][3] Indirect augmentation of fetal hemoglobin to ameliorate the symptoms of hemoglobinopathies[3][5]